Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24100148 | 0.85 | GPR84 (1.00) | GPR84RAB9AKMT2AMEN1NR4A2 | |
| SCHEMBL8530662 | 0.84 | GPR84 (0.79) | GPR84KMT2AMEN1NR4A2CDK2 | |
| SCHEMBL2879193 | 0.83 | MEN1 (0.71) | GPR84RAB9AKMT2AMEN1HTR6 | |
| SCHEMBL4932422 | 0.83 | KMT2A (0.73) | GPR84RAB9AKMT2AMEN1CDK2 | |
| SCHEMBL16880265 | 0.82 | GPR84 (0.57) | GPR84RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL8998901 | 0.82 | MAPT (0.64) | GPR84KMT2AMEN1MAPTPOLB | |
| SCHEMBL17912677 | 0.82 | GPR84 (0.64) | GPR84RAB9ANR4A2CREBBPCDK2 | |
| SCHEMBL29251314 | 0.81 | GPR84 (0.78) | GPR84RAB9AKMT2AMEN1CDK2 | |
| SCHEMBL858565 | 0.81 | MET (0.63) | GPR84KMT2AHTR6MAPT | |
| SCHEMBL22769056 | 0.80 | KMT2A (0.59) | GPR84KMT2AMEN1NR4A2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-11535592-B2 | Antimicrobial compounds, compositions, and method | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200385348-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| EP-3089977-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015102426-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-07-09 | — | — | WO | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| CN-101426778-A | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | LPO, GPX4, GMPS | GPR84 4586/4885RAB9A 4211/4885KMT2A 4591/4885 |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | GPR84 187/4885RAB9A 1006/4885KMT2A 269/4885 |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC2, HDAC1, HDAC3 | GPR84 2522/4885RAB9A 2936/4885KMT2A 91/4885 |
| US-11535592-B2 | Antimicrobial compounds, compositions, and method | LPO, MPO, GMPS | GPR84 4616/4885RAB9A 4170/4885KMT2A 4615/4885 |
| US-20200385348-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | LPO, GPX4, GMPS | GPR84 4586/4885RAB9A 4211/4885KMT2A 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.